QNCX

Quince TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.20

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.90

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.35

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious and monitoring-oriented. Primary sources now point to a failed lead program, a restructuring/strategic review, debt cleanup, and a reverse split rather than a traditional development story [#PR-2026-01-29][#PR-2026-02-09][#PR-2026-03-30][#8-K-2026-04-09]. That creates real optionality if a transaction emerges, but the deterministic prior is still negative and the 10-K going-concern language keeps conviction capped [#10-K-2026-04-10].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-reverse-split trading and listing stabilizationHigh impact

Quince filed an 8-K on April 9, 2026 stating the 1-for-10 reverse stock split became effective at 11:59 p.m. Eastern Time on April 10, 2026 and split-adjusted trading began April 13, 2026; near-term price action and liquidity after the split are likely to drive technical volatility around the listing-stability narrative [#8-K-2026-04-09].

2026-09-30eventStrategic alternative outcome after debt cleanupHigh impact

Quince engaged LifeSci Capital on February 9, 2026 to evaluate restructuring and strategic alternatives, and on March 30, 2026 said the $5.5 million EIB settlement fully discharged roughly $16.4 million of debt and removed an overhang that had constrained flexibility; the next material step is a disclosed transaction such as a merger, reverse merger, asset sale, partnership, or similar action [#PR-2026-02-09][#PR-2026-03-30].

2027-04-10catalystRunway and funding pressure remain centralHigh impact

The 2026-04-10 10-K says Quince had $17.8 million of cash, cash equivalents and short-term investments at December 31, 2025, raised about $20.4 million after year-end through the ATM, and still has substantial doubt about continuing as a going concern while needing additional funding to execute a strategic transaction; that makes financing terms or merger economics a major medium-term driver [#10-K-2026-04-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology